DongKook Pharmaceutical Co., Ltd.

DongKook Pharmaceutical Co., Ltd. logo
🇰🇷South Korea
Ownership
Public
Established
1992-01-01
Employees
1.1K
Market Cap
-
Website
http://www.dkpharm.co.kr
Clinical Trials
Related News

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Phase 3
Recruiting
Conditions
Advanced Prostate Cancer
Interventions
Drug: DKF-MA102
First Posted Date
2024-07-08
Last Posted Date
2024-07-08
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
154
Registration Number
NCT06490328
Locations
🇰🇷

Ewha Womans University mokdong Hospital, Seoul, Korea, Republic of

Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee

Not Applicable
Completed
Conditions
Osteoarthritis of Knee
Interventions
Device: DKM420
Device: Conjuran
First Posted Date
2023-09-01
Last Posted Date
2023-09-21
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
250
Registration Number
NCT06021444
Locations
🇰🇷

chung-Ang University Hospital, Seoul, Korea, Republic of

Efficacy and Safety of DKB-119 in Patients in Crow's Feet

Not Applicable
Active, not recruiting
Conditions
Crow's Feet
Interventions
Device: DKB-119
First Posted Date
2023-09-01
Last Posted Date
2023-09-13
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06021418
Locations
🇰🇷

Chungang-University Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety of AmBisome and DKF-5122

First Posted Date
2023-03-01
Last Posted Date
2023-03-01
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
38
Registration Number
NCT05749380
Locations
🇰🇷

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of

Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds

Not Applicable
Completed
Conditions
Nasolabial Folds
Interventions
Device: Juvederm ULTRA PLUS XC 1.0ml
Device: DKM-410
First Posted Date
2022-11-10
Last Posted Date
2022-11-14
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
82
Registration Number
NCT05612958
Locations
🇰🇷

Chung-Ang University Hospital, Seoul, Korea, Republic of

Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases

First Posted Date
2022-01-12
Last Posted Date
2022-01-12
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
158
Registration Number
NCT05188924
Locations
🇰🇷

Youngsung, Seoul, Korea, Republic of

Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia

First Posted Date
2021-07-01
Last Posted Date
2023-09-21
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
667
Registration Number
NCT04947631
Locations
🇰🇷

Ewha Womans University mokdong Hospital, Seoul, Korea, Republic of

Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: DKF-310
Drug: Placebo
First Posted Date
2016-03-01
Last Posted Date
2020-04-06
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
44
Registration Number
NCT02695004
Locations
🇰🇷

Seoul National Univ. Bundang Hospital, Seongnam, Korea, Republic of

Safety and Pharmacokinetic Characteristics of DKF-313

First Posted Date
2015-02-02
Last Posted Date
2021-07-06
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
54
Registration Number
NCT02352311
Locations
🇰🇷

Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of

Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride

First Posted Date
2013-09-16
Last Posted Date
2015-01-26
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
47
Registration Number
NCT01942551
Locations
🇰🇷

Chungnam National University Hospital, Daejeon, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy